DGAP-News: Evotec SE
/ Key word(s): Miscellaneous
12.11.2020 / 07:30
The issuer is solely responsible for the content of this announcement.
Hamburg, Germany, 12 November 2020:
The Dorothy Crowfoot Hodgkin Campus will boast the co-location of in vitro pharmacology and protein sciences, structural biology, drug metabolism and pharmacokinetics, computational, synthetic, and medicinal chemistry, formulation sciences, development chemistry and API manufacture. The co-location of these critical scientific functions enables excellent communication and rapid and inventive problem-solving at the interfaces of disciplines as well as accelerating the speed of iterative cycles in the drug discovery and development processes, turning the site into a fully integrated R&D centre.
Evotec’s campus at Milton Park already benefits from the strong relationships and proximity with the Diamond Light Source at Harwell, making it a centre of excellence in structure-based drug design. The location also facilitates excellent partnership opportunities in the Oxford and UK-wide academic and biotech scene.
With over 600 employees on site, Evotec’s Dorothy Crowfoot Hodgkin Campus now joins Evotec’s sites in Toulouse and Verona as one of three fully integrated powerhouses of capacity, capabilities and know-how in integrated R&D for the benefit of its partners.
Dr Craig Johnstone, Chief Operating Officer of Evotec, said: “Successful, fully-integrated drug discovery and development requires know-how and expertise as well as cutting-edge technologies and capabilities. We are delighted to extend our breadth of fully-integrated R&D sites with this extension to our capabilities at our Abingdon site, which we are proud to name after the X-ray crystallography technology leader and Nobel laureate: Dorothy Crowfoot Hodgkin Campus.”
About Dorothy Crowfoot Hodgkin
Somerville gave her a research fellowship to be held for one year at Cambridge and the second at Oxford. Crowfoot returned to Somerville and remained there, except for brief intervals, for the remainder of her career. She quickly started to collect money for an X-ray apparatus and continued the X-ray analysis of natural products with a research focus on sterols and other biologically interesting molecules, including insulin and penicillin.
In 1946, Dorothy Crowfoot Hodgkin took part in the meetings which led to the foundation of the International Union of Crystallography. She was elected a Fellow of the Royal Society in 1947, a foreign member of the Royal Netherlands Academy of Sciences in 1956, and of the American Academy of Arts and Sciences (Boston) in 1958. In 1964, Dorothy Crowfoot Hodgkin received the Nobel Prize for Chemistry for solving the atomic structure of molecules such as penicillin and insulin, using X-ray crystallography.
ABOUT EVOTEC SE
FORWARD LOOKING STATEMENTS
Media Contact Evotec SE:
IR Contact Evotec SE:
12.11.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Manfred Eigen Campus / Essener Bogen 7|
|Phone:||+49 (0)40 560 81-0|
|Fax:||+49 (0)40 560 81-222|
|Listed:||Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1147532|
|End of News||DGAP News Service|